Key Points
- CEO John Duke bought 5,000 shares of Harvard Bioscience on March 16th at an average price of $5.01, a $25,050 purchase that raised his holding to 105,000 shares (a 5.0% increase).
- HBIO shares were reported down 2.8%, trading near $4.87 with a market cap of $217.8M and a negative P/E; analysts' consensus is a "Hold" with a consensus target price of $6.00 (1 Buy, 2 Hold, 1 Sell).
- Institutional investors own 80.87% of the company, and Corsair Capital notably increased its position by 1,008.7% to 1,108,692 shares, while several other funds initiated or raised stakes.
Harvard Bioscience, Inc. (NASDAQ:HBIO - Get Free Report) CEO John Duke bought 5,000 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was bought at an average cost of $5.01 per share, for a total transaction of $25,050.00. Following the transaction, the chief executive officer owned 105,000 shares of the company's stock, valued at $526,050. The trade was a 5.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Harvard Bioscience Trading Down 2.8%
Shares of Harvard Bioscience stock opened at $4.87 on Wednesday. The stock has a market cap of $217.79 million, a P/E ratio of -0.38 and a beta of 1.51. The company has a quick ratio of 0.41, a current ratio of 2.20 and a debt-to-equity ratio of 2.61. Harvard Bioscience, Inc. has a 12-month low of $2.81 and a 12-month high of $9.50. The business's 50 day moving average is $5.63 and its 200-day moving average is $5.66.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Harvard Bioscience in a research note on Monday, December 29th. New Street Research set a $6.00 target price on Harvard Bioscience in a research note on Friday. Zacks Research upgraded Harvard Bioscience to a "hold" rating in a research note on Thursday, December 11th. Finally, Benchmark reduced their price objective on shares of Harvard Bioscience from $20.00 to $6.00 and set a "speculative buy" rating for the company in a research report on Friday, March 13th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $6.00.
Get Our Latest Analysis on Harvard Bioscience
Institutional Investors Weigh In On Harvard Bioscience
A number of hedge funds and other institutional investors have recently modified their holdings of HBIO. Virtu Financial LLC bought a new stake in shares of Harvard Bioscience in the fourth quarter valued at about $40,000. XTX Topco Ltd bought a new position in Harvard Bioscience during the fourth quarter worth about $26,000. Corsair Capital Management L.P. increased its position in Harvard Bioscience by 1,008.7% during the fourth quarter. Corsair Capital Management L.P. now owns 1,108,692 shares of the medical instruments supplier's stock worth $741,000 after acquiring an additional 1,008,692 shares during the period. Meros Investment Management LP raised its stake in Harvard Bioscience by 32.6% in the 4th quarter. Meros Investment Management LP now owns 1,217,628 shares of the medical instruments supplier's stock worth $814,000 after purchasing an additional 299,369 shares in the last quarter. Finally, Essex Investment Management Co. LLC acquired a new stake in Harvard Bioscience in the 4th quarter worth about $124,000. Institutional investors and hedge funds own 80.87% of the company's stock.
About Harvard Bioscience
(
Get Free Report)
Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company's product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.
Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
